Transition-Metal-Free Access to Pyridocarbazoles from 2

Subscriber access provided by UNIVERSITY OF TOLEDO LIBRARIES

Article

Transition-Metal-Free Access to Pyridocarbazoles from 2-Alkynylindole-3-carbaldehydes via Azomethine Ylide Shalini Verma, Pawan K. Mishra, Manoj Kumar, Souvik Sur, and Akhilesh K. Verma J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.8b00980 • Publication Date (Web): 23 May 2018 Downloaded from http://pubs.acs.org on May 23, 2018

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

The Journal of Organic Chemistry

Transition-Metal-Free Access to Pyridocarbazoles from 2-Alkynylindole-3-carbaldehydes via Azomethine Ylide Shalini Verma†#, Pawan K. Mishra†#, Manoj Kumar†, Souvik. Sur‡ and Akhilesh K. Verma†* †Synthetic Organic Chemistry Research Laboratory, Department of Chemistry, University of Delhi, Delhi–110007, India; ‡Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi 110067, India: Email: [email protected]

ABSTRACT:

An

efficient

approach

for

the

synthesis

of

functionalized

tetrahydro-

pyrido/quinolinocarbazoles from 2-alkynylindole-3-carbaldehydes and L-proline utilizing a metal-free decarboxylative cyclization, ring expansion, and ring contraction strategy via the generation of azomethine ylide has been developed. The reaction of 2-alkynylindole-3-carbaldehydes with Lthioproline leads to the formation of γ-carbolines. By virtue of this expedient method, a diverse range of biologically active hetero-annulated carbazoles can be synthesized efficiently.

ACS Paragon Plus Environment

1

The Journal of Organic Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 2 of 38

INTRODUCTION Hetero-annulated carbazole framework is an important core motifs present in the wide range of natural products and pharmaceutically derived drugs.1 Among them, pyridocarbazoles is an integral part of numerous natural products, bioactive alkaloids, and pharmaceuticals.2 Analogs of the pyridocarbazoles such as 6H-pyridocarbazole (ellipticine, olivacine, elliprabin and ratelliptine) and 7H-pyridocarbazole exhibit prospective antitumor activity as an efficient DNA intercalating agents3 (Figure 1). Furthermore, metallo-pyridocarbazoles have been used as protein kinase inhibitors.4

Figure 1 Biologically important pyridocarbazoles derived anticancer agents A number of traditional approaches5 have been reported in the literature for the synthesis of pyridocarbazole derivatives. However, these methods have multistep synthetic operations with limited substrate scope. The 7H-pyridocarbazoles and quinolinocarbazoles are synthetically challenging frameworks which have not been much explored. Nagarajan and co-worker have explored the synthesis of functionalized annulated carbazoles using ruthenium/copper/ palladium catalysts by heteroannulation and intramolecular arylation.6 In 2005, Bowman group reported7 the synthesis of ellipticine derivatives in a multistep sequence. An elegant approach for the synthesis of polycyclic ring system using L-Proline and heteroaldehyde via azomethine ylide intermediate was reported by Seidel et al (Scheme 1a).8 In 2015, the palladium-catalyzed synthesis of heteroannulated carbazole was reported by Das group.9a In the same year, Kundu and co-worker reported the synthesis of annulated poly-heterocycles by exploiting ACS Paragon Plus Environment

2

Page 3 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


decarboxylative cyclization under metal-free condition.9b Recently, Liu et al. reported the transitionmetal catalyzed synthesis of pyrido[4,3-b]- and quino[4,3-b] carbazole skeleton via palladium catalyzed direct C–3 alkenylation of indoles (Scheme 1b).10 In recent years, Decarboxylative coupling reaction has emerged as a mechanistically distinct strategy for the formation of C-C and C-N bonds. There are several transition-metal-catalyzed decarboxylative reactions have been developed for the construction of a variety of heterocycles.11,12 In continuation of our

ongoing

efforts

for

the

synthesis

of

biologically important

heterocycles

using

o-

alkynylaldehydes,13,14 we envisioned our effort for the rapid access of carbazole analogs containing fused tetrahydro-pyrido/quinoline ring from 2-alkynylindole-3-carbaldehydes which has not been much explored and are still challenging. Scheme 1. Synthesis of Pyridocarbazoles Derivatives


3


Page 4 of 38

The striking feature of the present strategy involves the one-step construction of pyridocarbazole derivatives by the sequential formation of one C-N and two C-C bonds via decarboxylation/cyclization followed by ring expansion under transition-metal-free condition (Scheme 1c). RESULTS AND DISCUSSION Preparation of ortho-Alkynylaldehydes. To probe the viability of the designed tandem strategy, ortho-alkynylaldehydes 4a–v and 5a–b were readily prepared by standard Sonogashira cross-coupling reaction of commercially available and readily accessible ortho-haloaldehydes with terminal alkynes 3a-n (Scheme 2).15a-c This coupling procedure has readily accommodated a large variety of functional groups and provided the coupling products 4a–v and 5a–b in good to excellent yields. Scheme 2. Preparation of ortho-Alkynylaldehydes

In order to determine the optimal reaction conditions, a variety of additive and solvents were examined using 2-(phenylethynyl)-1H-indole-3-carbaldehyde 4a and L-proline 6a as our model substrates (Table 1). Inspired from the Kundu conditions, we perform the reaction of 4a with 6a using DMF as a solvent, the desired product 7a was obtained in 35% yield instead of hexahydropyrrolo[2,1b]oxazoles16 (entry 1). Other solvents such as DMA, DMSO, NMP and toluene were capable of promoting the transformation with low yields (entries 2-5). Subsequently, various parameters were screened using DMF as a solvent. Addition of 4 Å molecular sieves at 120 oC provided the desired product 7a in 40% yield (entry 6). Increasing the temperature from 120 to 130 oC improved the yield of the product 7a (entry 7). It was interesting to note that the use of 0.2 equiv of benzoic acid as an additive afforded the desired product 7a in 65% yield (entry 8). Further increase in loading of the additive, decreased the yield of product 7a (entries 9-10). Drop in the yield of product 7a was observed in the ACS Paragon Plus Environment

4

Page 5 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


absence of molecular sieves (entry 11). Further increase in temperature, declined the yield of 7a (entry 12). Inferior results were obtained when acetic acid was used as an additive (entry 13). The product 7a was fully characterized by 1H, 13C NMR, and HRMS. Table 1. Optimization of Reaction Conditionsa

additive (equiv)

solvent

T C

time (h)

yield(%)b 7a

1

-

DMF

120

4

35

2

-

DMA

120

4

30

3

-

DMSO

120

4

32

4

-

NMP

120

4

32

5

-

Toluene

120

4

15

6c

-

DMF

120

4

40

7c

-

DMF

130

4

48

entry

o

8c

PhCOOH (0.2)

DMF

130

1

65

9c

PhCOOH (0.3)

DMF

130

1

60

10 c

PhCOOH (0.4)

DMF

130

1

56

11 d

PhCOOH (0.2)

DMF

130

1

40

12 c

PhCOOH (0.2)

DMF

140

1

55

13 c

CH3COOH (0.2)

DMF

130

1

42

a

Reactions were performed using 0.5 mmol of 4a, 0.6 mmol of 6a in 2.0 mL of solvent. bIsolated yield, c4 Å MS, dWithout molecular sieves With the optimized reaction condition in hand, scope and generality of the reaction were explored (Table 2). The N-protected substrates 4b–c also gave the desired products 7b and 7c in 70 and 60% yields, respectively (entries 2–3). The structure of pyridocarbazole 7b was further supported by Xray crystallographic analysis (see, Figure S1; Supporting Information). The reaction was well tolerated with

substrates

having electron-donating and

electron- withdrawing substituents.

The o-


5


Page 6 of 38

alkynylaldehydes bearing electron-donating groups such as methoxy (4d), ethyl (4e), tert–butyl (4f), n– butyl (4g), and methyl (4h) on the arene, afforded the desired products 7d–h in 71-78% yields (entries 4–8). However, the reaction of electron-deficient substrate 4i-j bearing trifluoromethoxy and trifluoromethyl group at the distal end of the para position of phenyl ring furnished the desired products 7i and 7j in 62 and 60% yields respectively (entries 9–10). Thiophene substituted o-alkynylaldehydes 4k-l were compatible to afford the products 7k and 7l in 75 and 80% yields respectively (entries 11–12). Substrate 4m with an electron-deficient heterocycle (2–pyridyl) provided the product 7m in moderate yield (entry 13). Notably, substrates 4n–q having an aliphatic group attached to triple bond was successfully provided the desired product 7n–q in 54–62% yields (entries 14–17). Table 2. Scopes of Tetrahydropyridocarbazolesa,b

entry 1

substrate

amine 4a

yieldb (%)

product 7a

65

6a

2

4b

6a

7b

70

3

4c

6a

7c

60


6

Page 7 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


4

4d

6a

7d

75

5

4e

6a

7e

78

6

4f

6a

7f

71

7

4g

6a

7g

76

8

4h

6a

7h

73

9

4i

6a

7i

62

10

4j

6a

11

4k

6a

7j

7k

60

75


7


12

4l

6a

Page 8 of 38

HN

N Me

7l

80

S

13

4m

6a

7m

65

14

4n

6a

7n

60

15

4o

6a

7o

62

16

4p

6a

7p

58

17

4q

6a

7q

54

a

Reactions were performed using 2-alkynylindole-3-carbaldehydes 4 (0.5 mmol), proline 6a (0.6 mmol) and benzoic acid (0.2 equiv) in 2.0 mL of DMF at 130 °C for 1 h. bIsolated yield. We further extended the scope of proline derivative such as L-hydroxyproline 6b with various functionalized 2–alkynylindole–3–carbaldehydes under standard reaction condition (Table 3). Halogencontaining substrates 4r,s were also found viable for the reaction and furnished the desired products 8a–

b in 58-60% yields (entries 1–2). The reaction of substrates 4b, 4a, 4d, 4k and 4s with Lhydroxyproline 6b furnished the desired product 8c–g in 70–80% yield (entries 3–7).


8

Page 9 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Table 3. The Scope of ortho-Alkynylaldehydes and Prolinea,b

entry

substrate

amine

product

yieldb (%)

1

4r

8a

58

6a 2

Cl

HN

8b 4s

6a

60

N H

3

4b

8c

74

6b

4

4a

6b

8d

75

5

4d

6b

8e

70


9


Page 10 of 38

6

4k

6b

8f

80

7

4s

6b

8g

78

a

Reactions were performed using 2-alkynylindole-3-carbaldehydes 4 (0.5 mmol), L-hydroxyproline 6b (0.6 mmol) and benzoic acid (0.2 equiv) in 2.0 mL of DMF at 130 °C for 1h. bIsolated yield. Encouraged by the above results (Tables 2-3), we further extended the scope of this reaction for the synthesis of novel pentacyclic tetrahydroquinolinocarbazoles (9a–c) which are difficult to synthesize. The reaction of 9-ethyl-2-(phenylethynyl)-9H-carbazole-3-carbaldehyde 5a and 9-ethyl-6-methyl-2(phenyl ethynyl)-9H-carbazole-3-carbaldehyde 5b with proline 6a and hydroxyproline 6b provided the desired products 9a–c in 78–85% yield (Scheme 3). Scheme 3. Synthesis of Tetrahydroquinolino[7,8-b] carbazolesa,b

a

Reactions condition: o-alkynylaldehyde 4 (0.5 mmol), 6a-b (0.6 mmol) and benzoic acid (0.2 equiv) in 2.0 mL of DMF at 130 °C for 1-2 h. bIsolated yield.


10

Page 11 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Interestingly, when we performed the reaction of substrate 4a with (R)-4-thioproline (6c) under standard reaction (entry 8), no ring expansion product 7a was observed. The formation of another biologically important heterocycle γ-carboline17 10a was observed in 80% yield via elimination reaction (Scheme 4). Scheme 4. Ring Expansion vs Elimination

a

Reaction Condition: This reaction performed using 0.5 mmol of 4, benzoic acid (0.2

equiv) and thioproline 6c (0.6 mmol) in 2.0 mL of solvent at 130 oC for 4 h. bIsolated yield. With this chemistry, we have synthesized γ-carbolines 10a–b in 78-80% yields under metal-free condition. The electron-releasing and electron-withdrawing substrates were well tolerated to afford the desired product 10c–e in good yields. Halogen bearing o-alkynylaldehyde substrate was also successful to furnish the desired product 10f in 81% yield. It was noteworthy that the 2-(thiophen-3-ylethynyl)-1Hindole-3-carbaldehyde provided the product 10g–h in 70-78% yields. In addition, the reaction of 4n ACS Paragon Plus Environment

11


Page 12 of 38

bearing aliphatic alkynes with 6c also allowed an easy access to the synthesis of γ-carbolines 10i in moderate yield. Based on the enormous biological activity of pyridocarbazoles, we have achieved the synthesis of pyrido [3,2-c]carbazoles 11a–b and quinolino[3,2-c]carbazole 11c by the oxidation of compounds 7a, 8c, and 9b using DDQ at room temperature with excellent yields.(Scheme 5). Scheme 5. Synthesis of Pyrido/Quinolino Carbazoles

Based on the previous reports,8,9b,13 a plausible mechanism has been proposed in Scheme 6. The mechanism is initiated via condensation of 2-alkynylindole-3-carbaldehydes 4 with proline 6 to produce an imine intermediate A. Further decarboxylation of intermediate A leads to the generation of an azomethine ylide B. The ylide B is then converted into species F either by the path ‘a’ or path ‘b’ via formation of intermediate C, D and E. In path a, B undergoes cyclopropane formation to furnish intermediate C which subsequently undergoes ring expansion to generate intermediate D. Lone pair of nitrogen migrates to undergo 6-endo dig cyclization to give intermediate E. Further, E rearranges to give F. However in case of path b, intermediate B undergoes favourable 5-endo dig cyclization followed by the abstraction of proton to generate intermediate C', which on ring expansion leads to the generation of a stable benzyl cation D'. Intermediate D', readily undergoes ring contraction to yield E', which further rearranges to gave the final product 7/8. ACS Paragon Plus Environment

12

Page 13 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Scheme 6. Proposed Reaction Mechanism

To find out the application of these compounds we have performed the molecular docking study of eight compounds (8c–e, 9a–c, and 11a–b) and ellipticine18 (as standard) was done for finding their binding modes with double-stranded DNA (see; Table S1, Supporting Information). We found that out of eight selected compounds; six molecules fit more firmly as intercalator than ellipticine.18 The compounds 9c, 11b, 8b, 8c, 8a, and 11a were found to have better docking scores than the rest. Compound 9c having more fused aromatic ring systems with hydroxyl groups shows the most effective stacking interaction with DNA nucleotides with the best docking score of -8.39 as compared with rest of molecules and ellipticine (-7.49). The presence of hydroxyl groups increases the hydrogen bonding possibility with nucleotides along with Vander Waals interactions and pi-stacking in case of 9c.


13


Page 14 of 38

CONCLUSION In summary, we have developed an efficient, metal and protection-free protocol for the synthesis of highly functionalized pyrido/quinolino carbazole via in situ generation of azomethine ylide with excellent regioselectivity from easily accessible 2-alkynylindole-3-carbaldehydes starting material. It was established that electron-rich, electron-deficient and alkyl substituted alkynes can be used for the incorporation of a variety of functional groups in the products. The developed synthetic method also allows for the synthesis of free (NH) γ-carbolines under a metal-free condition. The molecular docking score of -8.39 of compound (R)-8-ethyl-5-phenyl-2,3,4,8-tetrahydro-1H-quinolino[7,8-b]carbazol-3-ol (9c) having hydroxyl groups showed better stacking interaction with nucleotides in comparison to the known DNA intercalator drug ellipticine (-7.49). This chemistry is general and expected to find application in a variety of organic synthesis.


14

Page 15 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


General Experimental General Method. 1

H NMR (400 MHz) and

13

C NMR (100 MHz) spectra were recorded in CDCl3/DMSO-d6. Chemical

shifts for protons and carbons are reported in ppm from tetramethylsilane and are referenced to the carbon resonance of the solvent. Data has been reported as follows: chemical shift, multiplicity (s = singlet, brs = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublet), coupling constants in Hertz and integration. High-resolution mass spectra were recorded on electrospray mass spectrometer. Crystal structure analysis was accomplished on single needles X-ray diffractometer. TLC analysis was performed on commercially prepared 60 F254 silica gel plates and visualized by either UV irradiation or by staining with I2. All purchased chemicals were used as received. All melting points are uncorrected. Reagents: All reagents were used directly as obtained commercially unless otherwise noted. Anhydrous forms of dimethylformamide, dimethylacetamide, dimethylsulfoxide, dioxane dichloroethane, diethyether, THF, toluene, hexanes, ethyl acetate, and CH2Cl2 were purchased from Merck Chemical Co. oxindole, N–methyloxindole, N–phenyloxindole, terminal alkynes, palladium (II) chloride, Lprolines, POBr3, 5-chloroisatin, 5-bromoisatin, Et3N and the palladium salts were purchased from Aldrich Chemical Co., Inc. Preparation of ortho–Alkynylaldehydes To probe the viability of the designed tandem strategy, o–alkynylaldehydes 4a-v and 5a-b were readily prepared by standard Sonogashira cross–coupling reaction of commercially available and readily accessible o–haloaldehydes substrates with terminal alkynes (Scheme 2). This coupling procedure has readily accommodated a large variety of functional groups and provided the coupling products in good to excellent yields. The structure and purity of known starting materials 4a-v and 5a-b were confirmed ACS Paragon Plus Environment

15


Page 16 of 38

by comparison of their physical and spectral data (1H NMR and 13C NMR) with those 4b15a , (4i, 4l, 4u, 4v)

15b

and (5a-b)15c reported in the literature.

2-(Phenylethynyl)-1H-indole-3-carbaldehyde (4a).The product was obtained as yellow needle (91.8 mg, 75%): mp: 160–165 °C: 1H NMR (400 MHz, CDCl3) δ: 10.25 (s, 1H), 9.20 (brs, 1H), 8.27 (d, J = 7.3 Hz, 1H), 7.48 (d, J = 7.8 Hz, 2H) , 7.36–7.22 (m, 6H);

13

C NMR (100 MHz, CDCl3) δ: 185.7, 135.8,

131.8, 129.7, 129.4, 128.6, 125.4, 124.4, 123.5, 122.0, 121.1, 120.7, 111.1, 98.3, 78.2; HRMS (ESITOF) m/z: [M+H]+ Calcd for [C17H12NO] 246.0919; found 246.0913. 1-Phenyl-2-(phenylethynyl)-1H-indole-3-carbaldehyde (4c).The product was obtained as brown needle (120.4 mg, 75%): mp 160–165 °C:1H NMR (400 MHz, CDCl3) δ:10.35 (s, 1H), 8.39 (dd, J = 6.9 and 1.5 Hz, 1H),7.60–7.50 (m, 6H),7.44–7.43 (m, 1H),7.35–7.33 (m, 1H),7.32–7.28 (m, 2H),7.26–7.24 (m, 2H),7.02–7.00 (m, 1H); 13C NMR (100 MHz, CDCl3) δ:185.5, 137.8, 136.0, 131.6, 130.6, 129.3, 128.8, 127.1, 125.9, 125.3, 124.3, 123.8, 122.0, 120.5, 120.2, 110.7, 96.0, 77.8; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C23H16NO] 322.1232, found 322.1210. 2-((4-Methoxyphenyl)ethynyl)-1H-indole-3-carbaldehyde (4d). The product was obtained as pale yellow needle (107.2 mg, 78%): mp 145–150 °C: 1H NMR (400 MHz, DMSO–d6) δ: 12.70 (s, 1H), 10.18 (s, 1H), 8.10 (dd, J = 2.3 and 8.4 Hz, 1H), 7.65–7.62 (m, 2H), 7.46–7.43 (m, 1H), 7.34–7.28 (m, 1H), 7.27– 7.22 (m, 1H), 7.03 (t, J = 6.1 Hz, 2H), 3.80 (s, 3H);

13

C NMR (100 MHz, DMSO–d6) δ:184.5, 160.5,

136.3, 133.5, 129.4, 124.8, 124.0, 122.9, 120.7, 119.1, 114.7, 112.4, 112.0, 97.6, 77.7, 55.4 ; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C18H14NO2] 276.1025, found 276.1021. 2–((4–Ethylphenyl)ethynyl)–1H–indole–3–carbaldehyde (4e). The product was obtained as pale yellow needle (103.7 mg, 76%): mp 185–190 °C: 1H NMR (400 MHz, CDCl3) δ: 10.22 (s, 1H), 9.27 (s, 1H), 8.25 (d, J = 8.7 Hz, 1H), 7.38 (d, J = 7.8 Hz, 2H), 7.31–7.29 (m, 1H), 7.26–7.18 (m, 2H), 7.11 (d, J = 8.2 Hz, 2H), 2.59 (q, J = 7.3 and 7.8 Hz, 2H), 1.17 (t, J = 7.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ: 185.7, 146.5, 135.8, 131.8, 129.8, 128.2, 125.3, 124.4, 123.4, 121.9, 120.5, 118.2, 111.1, 98.7, 28.9, 15.2; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C19H16NO] 274.1232, found 274.1251. ACS Paragon Plus Environment

16

Page 17 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


2-((4-tert-Butylphenyl)ethynyl)-1H-indole-3-carbaldehyde (4f). The product was obtained as pale yellow needle (123.4 mg, 82%) : mp 135–140 °C: 1H NMR (400 MHz, DMSO–d6) δ: 12.73(s, 1H), 10.19 (s, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 8.4 Hz, 2H), 7.45–7.42 (m, 3H), 7.29 (t, J = 7.6 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H), 1.22 (s, 9H); 13C NMR (100 MHz, DMSO–d6) δ: 184.4, 152.9, 136.3, 131.5, 129.0, 125.8, 124.8, 124.0, 122.9, 120.8, 119.4, 117.7, 112.0, 97.4, 78.3, 34.7, 30.7; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H20NO] 302.1545, found 302.1568. 2-((4-Butylphenyl)ethynyl)-1H-indole-3-carbaldehyde (4g).The product was obtained as pale yellow needle (120.4 mg, 80%): mp 130–135 °C: 1H NMR (400 MHz, CDCl3) δ: 10.23 (s, 1H), 9.91 (brs, 1H), 8.25 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 7.3 Hz, 3H), 7.24–7.15 (m, 2H), 7.02 (d, J = 7.8 Hz, 2H) , 2.49 (t, J = 7.8 Hz, 2H), 1.49–1.43 (m, 2H), 1.26–1.21(m, 2H), 0.82 (t, J = 7.1 Hz, 3H);

13

C NMR (100 MHz,

CDCl3) δ: 185.9, 145.1, 136.1, 131.7, 130.4, 128.6, 125.2, 124.4, 123.4, 121.8, 120.2, 118.2, 111.4, 98.7, 77.8, 35.6, 33.2, 22.2, 13.9; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H20NO] 302.1545, found 302.1568. 2-((3-(methyl)phenyl)ethynyl)-1H-indole-3-carbaldehyde (4h). The product was obtained as off-white needle (95.9 mg, 78%): mp 159–164 °C: 1H NMR (400 MHz, CDCl3) δ: 10.24 (s, 1H), 8.90 (s, 1H), 8.26 (d, J = 6.9 Hz, 1H), 7.32–7.21 (m, 7H), 2.30 (s, 3H); 13C NMR (100 MHz, CDCl3) δ: 185.6, 138.4, 135.8, 132.3, 130.7, 129.4, 128.9, 128.5, 125.4, 124.4, 123.5, 122.0, 120.9, 120.7, 111.0, 98.6, 77.8, 21.2; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C18H14NO] 260.1075, found 260.1059. 2-((4-(Trifluoromethyl)phenyl)ethynyl)-1H-indole-3-carbaldehyde (4j). The product was obtained as pale yellow needle (101.7 mg, 65%): mp 155–160 °C: 1H NMR (400 MHz, DMSO–d6) δ: 10.23 (s, 1H), 8.11 (d, J = 7.8 Hz, 1H), 7.90 (d, J = 8.2 Hz, 2H), 7.83 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 8.2 Hz, 1H), 7.34 (t, J = 6.9 Hz, 1H), 7.26 (t, J = 7.3 Hz, 1H);

13

C NMR (100 MHz, DMSO–d6) δ:184.7, 136.4,

132.5, 129.8, 129.4, 127.6, 125.8 (q, J =3.8 Hz, 1C), 125.2, 125.0, 123.9, 123.1, 122.5, 120.9, 120.0, 112.2, 95.4, 81.2; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C18H11F3NO] 314.0793, found 314.0807.


17


Page 18 of 38

2-(Thiophen-3-ylethynyl)-1H-indole-3-carbaldehyde (4k).The product was obtained as off-white needle (102.9 mg, 82%): mp 150–155 °C:1H NMR (400 MHz, DMSO–d6) δ: 12.77 (s, 1H), 10.16 (s, 1H), 8.15–8.14 (m, 1H), 8.10 (d, J = 7.6 Hz, 1H), 7.73–7.71 (m, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.40–7.39 (m, 1H), 7.35–7.29 (m, 1H), 7.27–7.23 (m, 1H);

13

C NMR (100 MHz, DMSO–d6) δ: 184.5, 136.3, 132.4,

129.6, 128.9, 127.7, 125.0, 124.0, 123.0, 120.8, 119.6, 119.4, 112.1, 92.8, 78.3; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C15H10NOS] 252.0483, found 252.0478. 2-(Pyridin-2-ylethynyl)-1H-indole-3-carbaldehyde (4m). The product was obtained as brown needle (95.9 mg, 78%): mp 145–150 °C: 1H NMR (400 MHz, DMSO–d6) δ: 10.21 (s, 1H), 8.67 (d, J = 4.6 Hz, 1H), 8.12 (d, J = 8.2 Hz, 1H), 7.94–7.89 (m,1H), 7.83–7.81(m, 1H), 7.63–7.58 (m, 1H), 7.55–7.46 (m, 1H), 7.37–7.33 (m, 1H), 7.29–7.25 (m, 1H);

13

C NMR (100 MHz, DMSO–d6) δ: 184.4, 150.5, 141.0,

137.1, 136.5, 128.1, 127.5, 125.3, 124.5, 123.9, 123.2, 120.9, 120.3, 112.3, 96.2, 77.7; HRMS (ESITOF) m/z: [M+H]+ Calcd for [C16H11N2O] 247.0871, found 247.0860. 2-(Cyclohexenylethynyl)-1H-indole-3-carbaldehyde (4o). The product was obtained as off white needle (93.4 mg, 75%) : mp 115–120 °C: 1H NMR (400 MHz, DMSO–d6) δ:12.59 (s, 1H), 10.04 (s, 1H), 8.06 (d, J = 7.6 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.28 (t, J = 6.9 Hz, 1H), 7.22 (t, J = 6.3 Hz, 1H), 6.43– 6.41 (m, 1H), 2.27–2.15 (m, 4H), 1.65–1.55 (m, 4H); 13C NMR (100 MHz, DMSO–d6) δ: 184.2, 138.9, 136.2, 129.5, 124.7, 123.9, 122.9, 120.6, 119.0, 118.9, 112.0, 99.3, 76.3, 28.1, 25.4, 21.6, 20.8; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C17H16NO] 250.1232, found 250.1223. 2-(Cyclohexylethynyl)-1H-indole-3-carbaldehyde (4p). The product was obtained as pale yellow needle (90.3 mg, 72%): mp 120–125 °C:1H NMR (400 MHz, CDCl3) δ: 10.18(s, 1H), 9.39 (brs, 1H), 8.29 (dd, J = 6.4 and 2.8 Hz, 1H),7.36–7.25 (m, 3H), 2.70–2.65 (m, 1H), 1.90–1.86 (m, 2H), 1.77–1.72 (m, 2H), 1.60–1.52 (m, 3H), 1.40–1.34 (m, 3H);

13

C NMR (100 MHz, CDCl3) δ: 185.9, 135.5, 130.9, 124.9,

124.3, 123.2, 121.7, 120.0, 111.0, 104.4, 69.9, 32.0, 29.8, 25.6, 24.6; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C17H18NO] 252.1388, found 252.1398.


18

Page 19 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


2-(Cyclopropylethynyl)-1H-indole-3-carbaldehyde (4q).The product was obtained as pale yellow needle (75.2 mg, 72%) : mp 100–105 °C: 1H NMR (400 MHz, DMSO–d6) δ: 12.50 (s, 1H), 9.99 (s, 1H), 8.04 (d, J = 7.6 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.28–7.24 (m, 1H), 7.22–7.18 (m, 1H), 1.73–1.69 (m, 1H), 1.01–0.96 (m, 2H), 0.91–0.88 (m, 2H); 13C NMR (100 MHz, DMSO–d6) δ: 184.3, 135.9, 130.2, 124.6, 123.9, 122.8, 120.6, 119.1, 111.9, 103.2, 65.2, 9.1; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C14H12NO] 210.0919, found 210.0938. 5-Bromo-2-(phenylethynyl)-1H-indole-3-carbaldehyde (4r). The product was obtained as pale yellow needle (121.5 mg, 75%): mp 200–205 °C:1H NMR (400 MHz, DMSO–d6) δ: 10.15 (s, 1H), 8.21 (d, J = 1.4 Hz, 1H), 7.70–7.68 (m, 2H),7.53–7.48 (m, 4H),7.45–7.39 (m, 2H); 13C NMR (100 MHz, DMSO–d6) δ: 184.5, 135.1, 131.8, 130.2, 129.4,129.0, 127.5, 125.7, 122.8, 120.5, 118.7, 115.7, 114.2, 97.7, 78.4; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C17H11BrNO] 324.0024, found 326.0055 ( 81Br). 5-Chloro-2-(phenylethynyl)-1H-indole-3-carbaldehyde (4s). The product was obtained as pale yellow needle (100.8 mg, 72%): mp 175–180 °C:1H NMR (400 MHz, DMSO–d6) δ:10.15 (s, 1H), 8.02 (s, 1H), 7.68 (d, J = 7.8Hz, 2H), 7.53–7.43 (m, 5H), 7.32–7.30 (m, 1H);

13

C NMR (100 MHz, DMSO–d6)

δ:184.4, 134.7, 131.8, 130.2,129.6, 129.0, 127.7, 125.0, 124.9, 120.4, 119.7, 118.8, 113.7, 97.6, 78.4; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C17H11ClNO] 280.0529, found 280.0530. 1-Phenyl-2-(thiophen-3-ylethynyl)-1H-indole-3-carbaldehyde (4t).The product was obtained as Brown needle (102.9 mg, 82%): mp 150–155 °C: 1H NMR (400 MHz, CDCl3) δ: 10.27 (s, 1H), 8.31–8.29 (m, 1H), 7.53–7.49 (m, 2H), 7.47–7.42 (m, 3H), 7.37–7.36 (m, 1H), 7.28–7.22 (m, 2H), 7.20–7.17 (m, 2H), 6.94–6.92 (m, 1H);

13

C NMR (100 MHz, CDCl3) δ: 185.7, 137.9, 136.1, 131.5, 129.6, 129.4, 128.8,

128.7, 128.5, 127.3, 125.4, 124.4, 123.9, 122.1, 121.2, 120.6, 110.8, 100.8, 78.1; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H14NOS] 328.0796, found 328.0810. General Procedure for the Synthesis of Functionalized tetrahydro pyridocarbazoles 7a-q and 8a-g In an oven-dried round bottom flask, a solution of o-alkynylaldehyde 4 (0.5 mmol), L-proline 6 (0.6 mmol) with benzoic acid (0.2 equiv) in 2.0 mL of dry DMF were added under inert atmosphere. The resulting reaction ACS Paragon Plus Environment

19


Page 20 of 38

mixture was heated at 130 °C for 1-2 h. Progression of the reaction was monitored by TLC analysis; after completion, the reaction was cooled to room temperature. The reaction mixture was diluted with ethyl acetate (10 mL) and water (15 mL). The layers were separated, and the organic layer was washed with saturated brine solution and dried over Na2SO4. Organic layer was concentrated under reduced pressure. The crude material so obtained was purified by column chromatography on silica gel (100−200) (hexane: ethyl acetate; 95/5). The structure and purity of known starting materials were confirmed by comparison of their physical and spectral data (1 H NMR, 13C NMR, and HRMS). 5-Phenyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (7a). The product was obtained as off white needle, mp: 165–170 °C (96.2 mg, 65%), 1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 7.8 Hz, 1H), 7.89 (s, 1H), 7.47–7.32 (m, 7H), 7.26–7.22 (m, 1H), 6.68–6.67 (m, 1H), 4.72 (brs, 1H), 3.56 (t, J = 3.6 Hz, 2H), 2.76 (t, J = 5.9 Hz, 2H), 2.00–1.95 (m, 2H); 13C NMR (100 MHz, CDCl3) δ:142.7, 141.3, 140.6, 139.2, 138.8, 129.4, 127.8, 126.5, 124.0, 122.7, 120.3, 119.1, 110.0, 109.5, 108.8, 101.1, 42.2, 26.0, 22.4; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H19N2] 299.1548, found 299.1540. 7-Methyl-5-phenyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (7b). The product was obtained as yellow needle (109.2 mg, 70%); mp 185–190 °C; 1H NMR (400 MHz, CDCl3) δ: 7.97 (d, J = 7.8 Hz, 1H), 7.48–7.36 (m, 7H),7.25–7.21 (m, 1H), 6.71 (s, 1H), 4.75 (brs, 1H), 3.77 (s, 3H), 3.58 (t, J = 5.7 Hz, 2H), 2.78 (t, J = 6.4 Hz, 2H), 2.02–1.96 (m, 2H); 13C NMR (100 MHz, CDCl3) δ: 143.0, 141.1, 140.8, 140.7, 140.4, 129.4, 127.9, 126.6, 123.7, 122.3, 120.2, 118.5, 109.2, 107.9, 107.8, 99.2, 42.2, 29.0, 26.0, 22.5; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C22H21N2] 313.1705, found 313.1697. 5,7-Diphenyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (7c). The product was obtained as brown needle (112.0 mg, 60%); mp 180–185 °C; 1H NMR (400 MHz, CDCl3) δ: 7.92, (d, J = 7.8 Hz, 1H), 7.46–7.45 (m, 4H), 7.33–7.17(m, 9H), 6.58 (s, 1H), 4.72 (brs, 1H), 3.52 (t, J = 5.5 Hz, 2H), 2.68 (t, J = 5.9 Hz, 2H), 1.94–1.88 (m, 2H);

13

C NMR(100 MHz, CDCl3) δ: 142.8, 141.3, 140.8, 140.4, 137.7,

133.6, 130.1, 129.7, 129.5, 129.4, 128.5, 127.8, 127.4, 127.3, 126.6, 124.0, 121.7, 120.3, 119.6, 110.1,


20

Page 21 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


109.2, 100.3, 42.3, 26.0, 22.4; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C27H23N2] 375.1861, found 375.1894. 5-(4-Methoxyphenyl)-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (7d). The product was obtained as brown needle (123.0 mg, 75%); mp 180–185 °C; 1H NMR (400 MHz, DMSO–d6) δ: 10.95 (s, 1H), 8.22 (d, J = 7.6 Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.31–7.25 (m, 3H), 7.10 (t, J = 7.6 Hz, 1H), 6.97 (d, J = 8.4 Hz, 2H), 6.55 (s, 1H),5.78 (s, 1H),3.79 (s, 3H), 3.44 (t, J = 4.6 Hz, 2H), 2.64 (t, J = 6.5 Hz, 2H), 1.82–1.77 (m, 2H); 13C NMR (100 MHz, DMSO–d6) δ: 157.9, 140.5,139.9, 139.3, 139.2, 135.0, 130.1, 123.3, 122.2, 121.0, 117.8, 113.3, 109.8, 107.6, 107.4, 100.0, 55.0, 40.1, 26.2, 22.1; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C22H21N2O] 329.1654, found 329.1640. 5-(4-Ethylphenyl)-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (7e). The product was obtained as yellow needle (127.0 mg, 78%); mp 115–120 °C; 1H NMR (400 MHz, CDCl3) δ: 7.91 (d, J = 7.8 Hz, 1H), 7.87(s, 1H), 7.32–7.30 (m, 4H),7.24–7.17 (m, 3H),6.66 (s, 1H), 4.65 (br s, 1H), 3.53 (t, J = 5.5 Hz, 2H), 2.75–2.68 (m, 4H),1.96–1.91 (m, 2H), 1.29 (t, J = 7.8 Hz, 3H);

13

C NMR (100 MHz, CDCl3) δ:

142.4, 141.3, 140.6, 140.0, 139.2, 138.8, 129.3, 127.3, 123.9, 122.8, 120.3, 119.1, 110.0, 109.7, 108.7, 101.2, 42.2, 28.5, 26.0, 22.5, 15.5; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C23H23N2] 327.1861, found 327.1884. 5-(4-tert-Butylphenyl)-2,3,4,7-tetrahydro-1H-pyrido[3,2-c] carbazole (7f). The product was obtained as off-white needle (125.6 mg, 71%); mp210–215 °C; 1H NMR (400 MHz, CDCl3) δ: 7.85 (d, J = 7.3 Hz, 1H), 7.80 (s, 1H), 7.36–7.34 (m, 2H), 7.26 (s, 1H), 7.25–7.24 (m, 3H),7.15–7.10 (m, 1H),6.59 (s, 1H), 3.46 (t, J = 6.4 Hz, 2H), 2.68 (t, J = 6.9 Hz, 2H), 1.89–1.83 (m, 2H),1.31 (s, 9H); 13C NMR (100 MHz, CDCl3) δ: 149.3, 141.2, 140.6, 139.7, 139.2, 138.8, 129.0, 124.7, 123.9, 122.8, 120.2, 119.0, 110.0, 109.7, 108.7, 101.2, 42.2, 34.5, 31.4, 26.1, 22.5; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C25H27N2] 355.2174, found 355.2191. 5-(4-Butylphenyl)-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (7g). The product was obtained as off white needle (134.0 mg, 76%); mp 205–210°C; 1H NMR (400 MHz, CDCl3) δ:7.89 (d, J = 7.8 Hz, 1H), ACS Paragon Plus Environment

21


Page 22 of 38

7.79(s, 1H), 7.31–7.26 (m, 4H),7.20–7.15 (m, 3H), 6.61(s, 1H), 4.61(brs, 1H), 3.50 (t, J = 5.0 Hz, 2H), 2.72 (t, J = 6.4 Hz, 2H), 2.65 (t, J = 7.8 Hz, 2H), 1.94–1.88 (m, 2H), 1.69–1.61 (m, 2H), 1.45–1.36 (m, 2H), 0.98–0.94 (m, 3H); 13C NMR (100 MHz, CDCl3) δ:141.3, 141.1, 140.6, 139.9, 139.2, 138.8, 129.2, 127.8, 123.9, 122.7, 120.2, 119.0, 110.0, 109.6, 108.7, 101.2, 42.2, 35.4, 33.6, 26.0, 22.5, 22.4, 14.0; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C25H27N2] 355.2174,found 355.2191. 5-m-Tolyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (7h). The product was obtained as yellow needle (113.8 mg, 73%); mp 100–105 °C; 1H NMR (400 MHz, CDCl3) δ: 7.94–7.91 (m, 2H), 7.40–7.28 (m, 3H), 7.23–7.21 (m, 2H), 7.19–7.15 (m, 2H), 6.70 (s, 1H), 4.70 (brs, 1H), 3.56 (t, J = 5.5 Hz, 2H), 2.73 (t, J = 6.2 Hz, 2H), 2.41(s, 3H), 2.00–1.94 (m, 2H);13C NMR (100 MHz, CDCl3) δ:142.7, 141.5, 140.7, 139.2, 138.8, 137.4, 130.1, 127.7, 127.3, 126.4, 123.9, 122.9, 120.3, 119.1, 110.0, 109.6, 108.8, 101.0, 42.2, 26.0, 22.5, 21.5; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C22H21N2] 313.1705, found 313.1697. 7-Methyl-5-(4-(trifluoromethoxy)phenyl)-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole

(7i).

The

product was obtained as off–white needle (123.0 mg, 62%); mp 150–155 °C; 1H NMR (400 MHz, CDCl3) δ: 7.87 (d, J = 7.6 Hz, 1H), 7.38–7.28 (m, 4H), 7.20–7.14 (m, 3H), 6.57 (s, 1H), 4.69 (s, 1H), 3.69 (s, 3H), 3.49 (t, J = 4.6 Hz, 2H), 2.65 (t, J = 6.1 Hz, 2H), 1.93–1.87 (m, 2H);13C NMR (100 MHz, CDCl3) δ: 148.0, 141.7, 140.9, 140.7, 140.4, 139.6, 130.7, 123.9, 122.1, 120.4, 120.3, 118.7, 109.0, 108.1, 107.9, 99.1, 42.2, 29.0, 26.0, 22.4; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C23H20F3N2O] 397.1528, found 397.1519. 5-(4-(Trifluoromethyl)phenyl)-2,3,4,7-tetrahydro-1H-pyrido [3,2-c]carbazole (7j). The product was obtained as red brown needle (99.6 mg, 60%); mp 115–120 °C; 1H NMR (400 MHz, CDCl3) δ: 7.97 (s, 1H), 7.86 (d, J = 7.8 Hz, 1H), 7.59–7.54 (m, 2H), 7.44–7.42 (m, 2H), 7.33–7.26 (m, 2H), 7.17–7.12 (m, 1H), 6.58 (s, 1H), 3.49 (t, J = 5.7 Hz, 2H), 2.62 (t, J = 6.4 Hz, 2H), 1.92–1.86 (m, 2H); 13C NMR (100 MHz, CDCl3) δ:146.5, 140.8, 139.7, 139.3, 138.8, 133.4, 132.6, 129.7, 124.8 (q, J = 2.9 Hz, 1C), 124.2,


22

Page 23 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


122.6, 120.4, 119.3, 110.1, 109.1, 100.8, 42.1, 25.9, 22.3; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C22H18F3N2] 367.1422, found 367.1400. 5-(Thiophen-3-yl)-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (7k). The product was obtained as red brown needle (114 mg, 75%) ; mp 105–110 °C; 1H NMR (400 MHz, CDCl3) δ: 7.85–7.83(m, 2H), 7.28–7.23 (m, 3H), 7.14–7.11 (m, 3H), 6.67–6.66 (m, 1H), 3.47 (t, J = 5.9 Hz, 2H), 2.74 (t, J = 5.5 Hz, 2H), 1.93–1.87 (m, 2H);13C NMR (100 MHz, CDCl3) δ: 143.0, 140.8, 139.2, 138.8, 135.7, 129.4, 124.4, 124.0, 122.8, 122.3, 120.3, 119.1, 110.1, 109.9, 109.0, 101.0, 42.1, 26.0, 22.4; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C19H17N2S] 305.1112, found 305.1136. 7-Methyl-5-(thiophen-3-yl)-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole

(7l).

The

product

was

obtained as yellow needle (127.2 mg, 80%); mp 100–105°C; 1H NMR (400 MHz, CDCl3) δ: 7.86 (d, J = 7.8 Hz, 1H), 7.31–7.28 (m, 3H), 7.20–7.12 (m, 3H), 6.69 (s, 1H), 3.70 (s, 3H),3.49 (t, J = 5.5 Hz, 2H), 2.76 (t, J = 6.2 Hz, 2H), 1.95–1.91 (m, 2H); 13C NMR (100 MHz, CDCl3) δ: 143.2, 140.8, 140.7, 140.4, 135.5, 129.4, 124.5, 123.8, 122.31, 122.27, 120.2, 118.6, 109.6, 108.1, 107.9, 99.1, 42.2, 29.0, 26.0, 22.4; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C20H19N2S] 319.1269, found 319.1260. 5-(Pyridin-2-yl)-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (7m). The product was obtained as brown needle (97.0 mg, 65%); mp 180–185 °C; 1H NMR (400 MHz, DMSO–d6) δ: 11.00 (s, 1H), 8.63 (d, J = 4.1 Hz, 1H), 8.22 (d, J = 7.8 Hz, 1H), 7.84–7.80 (m, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.32–7.25 (m, 2H), 7.09 (t, J = 6.9 Hz, 1H), 6.69 (s, 1H),5.80 (s, 1H), 3.44–3.35 (m, 2H), 2.71 (t, J = 5.9 Hz, 2H), 1.82–1.76 (m, 2H);

13

C NMR (100 MHz, DMSO–d6) δ: 160.6, 148.7, 140.6,

139.4, 139.1, 139.0, 136.2, 124.1, 123.6, 122.1, 121.5, 121.2, 117.9, 109.9, 108.4, 107.7, 100.3, 41.4, 25.7, 22.0; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C20H18N3] 300.1501, found 300.1522. 7-Methyl-5-phenethyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c] carbazole (7n). The product was obtained as off-white needle (102.0 mg, 60%); mp 125–130 °C; 1H NMR (400 MHz, CDCl3) δ:7.83 (d, J = 7.6 Hz, 1H), 7.33–7.10 (m, 9H), 6.58(s, 1H), 3.69(s, 3H), 3.45 (t, J = 5.3 Hz, 2H), 2.93–2.88 (m, 4H), 2.82 (t, J = 6.1 Hz, 2H), 2.07–2.01 (m, 2H);

13

C NMR (100 MHz, CDCl3) δ: 142.4, 141.1, 140.6, 140.4,


23


Page 24 of 38

139.3, 128.42, 128.35, 125.9, 123.4, 122.4, 120.0, 118.4, 109.8, 107.7, 107.5, 98.1, 42.0, 37.3, 36.2, 29.0, 23.8, 22.6; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C24H25N2] 341.2018, found 341.2009. 5-Cyclohexenyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazoles (7o) . The product was obtained as brown needle (93.6 mg, 62%); mp 115–120 °C; 1H NMR (400 MHz, DMSO–d6) δ: 10.81 (s, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 7.6 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.03 (t, J = 6.9 Hz, 1H), 6.40 (s, 1H),5.74 (s, 1H),5.64 (s, 1H),3.39(s, 2H), 2.70 (t, J = 5.3 Hz, 2H), 2.17–2.13 (m, 4H), 1.84–1.83 (m, 2H),1.71–1.63 (m, 4H);

13

C NMR (100 MHz, DMSO–d6) δ: 143.0, 140.2, 139.8, 139.2, 139.1, 124.1,

123.0, 122.3, 120.8, 117.7, 109.6, 107.3, 107.0, 98.4, 54.9, 40.1, 30.0, 24.9, 22.8, 22.1, 21.9; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H23N2] 303.1861, found 303.1861. 5-Cyclohexyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (7p). The product was obtained as red brown needle (87.8 mg, 58%); mp 110–115 °C; 1H NMR (400 MHz, CDCl3) δ: 7.86 (d, J = 7.8 Hz, 1H), 7.82 (s, 1H), 7.29–7.25 (m, 2H), 7.17–7.12 (m, 1H), 6.68 (s, 1H), 4.55 (brs, 1H), 3.48 (t, J = 5.5 Hz, 2H), 2.88 (t, J = 6.4 Hz, 2H), 2.81–2.76 (m, 1H), 2.12–2.07(m, 2H), 1.87 (d, J = 7.8 Hz, 4H), 1.81–1.77 (m, 1H), 1.50–1.19 (m, 5H);13C NMR (100 MHz, CDCl3) δ: 145.7, 140.8, 139.3, 139.1, 123.5, 123.0, 120.0, 118.8, 109.8, 109.4, 107.9, 97.0, 41.9, 40.0, 34.2, 27.3, 26.5, 23.5, 22.7; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H25N2] 305.2018, found 305.2018. 5-Cyclopropyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (7q). The product was obtained as yellow needle (70.7 mg, 54%); mp 110–115 °C:1H NMR (400 MHz, CDCl3) δ:7.81–7.76 (m, 2H),7.26–7.20 (m, 2H), 7.09 (t, J = 6.9 Hz, 1H), 6.45 (s, 1H), 4.49 (brs, 1H), 3.44 (t, J = 5.27 Hz, 2H), 2.94 (t, J = 6.4 Hz, 2H), 2.09–2.03 (m, 2H), 1.90–1.83 (m, 1H), 0.88–0.80 (m, 2H), 0.61–0.57 (m, 2H); 13C NMR (100 MHz, CDCl3) δ: 140.8, 140.6, 139.02, 138.99, 123.6, 122.9, 120.1, 118.9, 112.2, 109.9, 108.2, 97.6, 42.0, 24.0, 22.6,14.1, 6.8; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C18H19N2] 263.1548, found 263.1571 10-Bromo-5-phenyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (8a). The product was obtained as brown needle (109.0 mg, 58%); mp 110–115 °C; 1H NMR (400 MHz, CDCl3) δ: 7.94 (s, 1H), 7.86 (s, ACS Paragon Plus Environment

24

Page 25 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


1H), 7.35–7.27 (m, 6H), 7.16–7.11 (m, 1H), 6.57 (s, 1H), 3.46 (t, J = 5.3 Hz, 2H), 2.63 (t, J = 6.4 Hz, 2H), 1.88–1.82 (m, 2H);

13

C NMR (100 MHz, CDCl3) δ: 142.5, 142.1, 140.8, 139.2, 137.8, 129.3,

127.9, 126.7, 126.6, 124.6, 122.9, 111.7, 111.3, 110.0, 108.1, 101.1, 42.2, 26.0, 22.3; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H18BrN2] 377.0653, found 377.0674 (79Br). 10-Chloro-5-phenyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazole (8b). The product was obtained as red brown needle (99.6 mg, 60%); mp 115–120 °C; 1H NMR (400 MHz, CDCl3) δ:7.84 (s, 1H), 7.80 (s, 1H), 7.33–7.26 (m, 5H), 7.19–7.16 (m, 2H), 6.57 (s, 1H), 4.48 (brs, 1H), 3.45 (t, J = 5.5 Hz, 2H), 2.63 (t, J = 6.4 Hz, 2H), 1.89–1.82 (m, 2H);

13

C NMR (100 MHz, CDCl3) δ: 142.5, 142.0, 140.7, 139.4,

137.5, 129.3, 127.9, 126.7, 124.3, 123.9, 119.9, 110.8, 109.9, 108.2, 101.1, 42.2, 26.0, 22.3; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H18ClN2] 333.1159, found 333.1154. (R)-7-Methyl-5-phenyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazol-3-ol

(8c).

The

product

was

obtained as dark brown needle (121.3 mg, 74%); mp 130–135 °C;1H NMR (400 MHz, CDCl3) δ: 7.94 (d, J = 8.4 Hz, 1H), 7.51 (t, J = 9.2 Hz, 1H), 7.44–7.41 (m, 5H), 7.39–7.31 (m, 3H), 7.22–7.21 (m, 1H), 6.75 (s, 1H), 4.27–4.25 (m, 1H), 3.76 (s, 3H), 3.60–3.58 (m, 1H), 3.51–3.47 (m, 1H), 3.03–2.99 (m, 1H), 2.81–2.76 (m, 1H);13C NMR (100 MHz, CDCl3) δ: 142.5, 142.0, 140.6, 140.5, 139.6, 134.0, 129.3, 128.9, 128.5, 128.0, 126.8, 124.1, 122.0, 120.3, 118.8, 108.1, 105.8, 100.4, 63.5, 47.7, 34.4, 29.0; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C22H21N2O] 329.1654, found 329.1651. (R)-5-Phenyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazol-3-ol (8d). The product was obtained as brown needle (110 mg, 70%); mp 110–115 °C; 1H NMR (400 MHz, CDCl3) δ: 8.06(s, 1H), 7.90 (d, J = 7.8 Hz, 1H), 7.40–7.33 (m, 7H), 7.23–7.19 (m, 1H), 6.72–6.71 (m, 1H), 4.23 (s, 3H), 3.56–3.53 (m, 1H),3.47–3.43 (m, 1H), 2.99–2.94 (m, 1H), 2.76–2.71 (m, 1H);13C NMR (100 MHz, CDCl3) δ: 142.2, 142.1, 139.5, 139.2, 139.0, 129.3, 128.0, 126.7, 124.2, 122.4, 120.3, 119.3, 110.2, 108.6, 106.1, 102.3, 63.4, 47.6, 34.4; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H19N2O] 315.1497, found 315.1491. (R)-5-(4-Methoxyphenyl)-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazol-3-ol (8e). The product was obtained as off white needle (137.6 mg, 80%); mp 225–230 °C; 1H NMR (400 MHz, DMSO–d6) δ: ACS Paragon Plus Environment

25


Page 26 of 38

10.84 (s, 1H), 8.10 (d, J = 7.6 Hz, 1H), 7.27–7.24 (m, 1H), 7.17–7.14 (m, 3H), 6.98–6.94 (m, 1H), 6.86– 6.84 (m, 2H), 6.44–6.43 (m, 1H), 5.65–5.62 (m, 1H),4.76 (s, 1H), 3.78–3.73 (m, 1H),3.66 (s, 3H), 3.41– 3.39 (m, 1H), 3.00 (t, J = 9.2 Hz, 1H), 2.63–2.59 (m, 1H), 2.52–2.46 (m, 1H);

13

C NMR (100 MHz,

DMSO–d6) δ: 158.0, 140.3, 139.9, 139.4, 139.3, 134.9, 130.2, 123.4, 122.2, 121.0, 117.9, 113.4, 109.9, 107.5, 106.1, 100.4, 63.2, 55.1, 48.1, 35.6; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C22H21N2O2] 345.1603, found 345.1589. (R)-5-(Thiophen-3-yl)-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazol-3-ol (8f). The product was obtained as brown needle (124.8 mg, 78%); mp 100–105 °C; 1H NMR (400 MHz, DMSO–d6) δ: 10.97 (s, 1H), 8.22 (d, J = 7.6 Hz, 1H), 7.59–7.57 (m, 1H), 7.46–7.45 (m, 1H),7.38 (d, J = 8.4 Hz, 1H), 7.26–7.23 (m, 2H), 7.08 (t, J = 7.6 Hz, 1H), 6.67 (s, 1H),5.78 (s, 1H), 4.92–4.91 (m, 1H), 3.93–3.91 (m, 1H), 3.54– 3.51 (m, 1H), 3.17–3.12 (m, 1H), 2.82–2.83 (m, 1H), 2.73–2.48 (m, 1H); 13C NMR (100 MHz, DMSO– d6) δ: 143.0, 140.0, 139.3, 135.1, 129.3, 125.2, 123.5, 122.5, 122.1, 121.1, 117.9, 109.9, 107.7, 106.2, 100.3, 63.1, 48.0, 35.5, 27.0; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C19H17N2OS] 321.1062, found 321.1061. (R)-10-Chloro-5-phenyl-2,3,4,7-tetrahydro-1H-pyrido[3,2-c]carbazol-3-ol (8g). The product was obtained as dark brown needle (111.6 mg, 64%); mp 110–115°C; 1H NMR (400 MHz, DMSO–d6) δ: 11.05 (s, 1H), 8.22 (d, J = 7.6 Hz, 1H), 7.34–7.22 (m, 6H), 7.17–7.15 (m, 1H), 6.46 (s, 1H), 5.83 (s, 1H), 4.77 (d, J = 3.7 Hz, 1H), 3.80–3.73 (m, 1H),3.41–3.38 (m, 1H), 3.01 (t, J = 10.8 Hz, 1H), 2.63– 2.57 (m, 1H), 2.51–2.45 (m, 1H); 13C NMR (100 MHz, DMSO–d6) δ: 142.6, 141.3, 140.0, 137.8, 129.0, 128.0, 126.5, 123.4, 123.1, 122.4, 120.4, 110.9, 106.9, 106.1, 100.2, 62.9, 47.7, 35.5; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H18ClN2O] 349.1108, found 349.1103. General Procedure for the Synthesis of Functionalized tetrahydro quinolinocarbazoles 9a-c. In an oven-dried round bottom flask, a solution of o-alkynylheteroarylaldehyde 5a-b (0.5 mmol), L-proline 6 (0.6mmol), benzoic acid (0.2 equiv) and 4Å molecular sieves in 2.0 mL in dry DMF were added under inert atmosphere. The resulting reaction mixture was heated at 130°C for 3-4h. The reaction mixture was diluted ACS Paragon Plus Environment

26

Page 27 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


with ethyl acetate (10 mL) and water (15 mL). The layers were separated, and the organic layer was washed with saturated brine solution and dried over Na2SO4. Organic layer was concentrated under reduced pressure. The crude material so obtained was purified by column chromatography on silica gel (100−200) (hexane:ethylacetate; 95/5). The structure and purity of known starting materials were confirmed by comparison of their physical and spectral data (1 H NMR, 13C NMR, and HRMS). 8-Ethyl-5-phenyl-2,3,4,8-tetrahydro-1H-quinolino[7,8-b] carbazole (9a). The product was obtained as a yellow solid (150.6 mg, 85%); mp 275–280 °C; 1H NMR (400 MHz, CDCl3) δ: 8.53 (s, 1H), 8.13 (d, J = 7.3 Hz, 1H), 7.55 (s, 1H), 7.49–7.41 (m, 6H), 7.38–7.31 (m, 2H), 7.21–7.16 (m, 1H), 4.32 (q, J = 6.9 and 14.2 Hz, 2H), 3.56 (t, J = 5.5 Hz, 2H), 2.75 (t, J = 6.4 Hz, 2H), 1.99–1.93 (m, 2H), 1.41 (t, J = 7.1 Hz, 3H);13C NMR (100 MHz, CDCl3) δ:142.5, 142.4, 140.9, 139.7, 138.9, 133.8, 133.1, 131.7, 129.3, 127.9, 126.7, 126.6, 124.2, 123.2, 120.6, 118.5, 118.1, 110.6, 107.9, 103.7, 42.5, 37.5, 26.4, 22.3, 13.3; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C27H25N2] 377.2018, found 377.2015. 8-Ethyl-11-methyl-5-phenyl-2,3,4,8-tetrahydro-1H-quinolino[7,8-b]carbazoles (9b).The product was obtained as a yellow needle (160.1 mg, 82%); mp 270–275 °C; 1H NMR (400 MHz, CDCl3) δ: 8.46 (s, 1H), 7.98 (s, 1H), 7.53 (s, 1H), 7.47–7.40 (m, 4H), 7.37–7.29 (m, 2H), 7.26–7.21 (m, 2H), 4.31 (q, J = 7.3and 14.2 Hz, 2H), 3.55 (t, J = 4.6 Hz,2H), 2.74 (t, J = 5.9 Hz, 2H), 2.54 (s, 3H), 1.97–1.91 (m, 2H), 1.40 (t, J = 7.3 Hz, 3H);13C NMR (100 MHz, CDCl3) δ: 142.6, 140.9, 140.7, 140.0, 139.4, 131.7, 129.3, 127.8, 126.6, 124.1, 123.4, 120.8, 117.8, 117.6, 110.8, 110.4, 107.7, 103.6, 42.5, 37.6, 26.4, 22.5, 21.3, 13.2; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C28H27N2] 391.2174, found 391.2175. (R)-8-Ethyl-11-methyl-5-phenyl-2,3,4,8-tetrahydro-1H-quinolino[7,8-b] carbazol-3-ol (9c).The product was obtained as a yellow needle (158.5 mg, 78%); mp 300–305 °C; 1H NMR (400 MHz, CDCl3) δ: 8.48 (s, 1H), 8.01 (s, 1H), 7.55 (s, 1H), 7.46–7.43 (m, 4H), 7.41–7.33 (m, 3H), 7.26–7.24 (m, 1H), 4.31 (q, J = 7.3 and 14.6 Hz, 2H), 4.26–4.22 (m, 1H), 3.98 (brs 1H), 3.54–3.46 (m, 2H), 3.05–3.00 (m, 1H), 2.79– 2.73 (m, 1H), 2.58 (s, 3H), 1.42 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ: 142.0, 141.1, 140.6, ACS Paragon Plus Environment

27


Page 28 of 38

140.0, 138.4, 131.7, 129.5, 128.9, 128.2, 127.9, 127.6, 127.0, 126.4, 124.1, 123.2, 121.1, 118.8, 117.3, 110.9, 108.0, 107.7, 103.8, 63.2, 47.7, 37.5, 34.8, 21.5, 13.5; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C28H27N2O] 407.2123, found 407.2095. General Procedure for the Synthesis of Functionalized γ-Carbolines 10a-i. In an oven-dried round bottom flask, a solution of o-alkynylheteroaryl aldehyde 4 (0.5 mmol), L-thioproline 6c (0.6 mmol), benzoic acid (0.2 equiv.) and 4Å molecular sieves in 2.0 mL dry DMF were added under inert atmosphere. The resulting reaction mixture was heated at 130°C for 2−4h. Progression of the reaction was monitored by TLC analysis; after complete consumption of starting material, the reaction was cooled to room temperature. The reaction mixture was diluted with ethyl acetate (10 mL) and water (15 mL). The layers were separated, and the organic layer was washed with saturated brine solution and dried over Na2SO4. Organic layer was concentrated under reduced pressure. The crude material so obtained was purified by column chromatography on silica gel (100−200) (hexane:ethylacetate; 80/20). The structure and purity of known starting materials were confirmed by comparison of their physical and spectral data (1H NMR, 13C NMR, and HRMS). 3-Phenyl-5H-pyrido[4,3-b]indole (10a). The product was obtained as a brown needle (97.2 mg, 80%); mp 120–125 °C: 1H NMR (400 MHz, DMSO-d6) δ: 11.82 (s, 1H), 9.41 (s, 1H), 8.23 (d, J = 7.8 Hz, 1H), 8.15 (d, J = 7.3 Hz, 2H), 7.96 (s, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.51–7.46 (m, 2H), 7.45–7.39 (m, 2H),7.26 (t, J = 6.9 Hz, 1H);

13

C NMR (100 MHz, DMSO-d6) δ: 151.3, 145.0, 142.0, 140.3, 139.4,

128.7, 128.5, 126.8, 120.7, 120.6, 120.2, 118.8, 111.6, 102.6; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C17H13N2] 245.1079, found 245.1075. 5-Methyl-3-phenyl-5H-pyrido[4,3-b]indole (10b).The product was obtained as a yellow needle (100.6 mg, 78%); mp 120−125 °C; 1H NMR (400 MHz, CDCl3) δ: 9.25 (s, 1H), 8.06 (d, J = 7.3 Hz, 1H), 8.02−8.00 (m, 2H), 7.57 (s, 1H), 7.46−7.39 (m, 3H), 7.34−7.31 (m, 2H), 7.26−7.22 (m, 1H), 3.76 (s, 3H);

13

C NMR (100 MHz, CDCl3) δ: 153.5, 146.0, 142.2, 141.4, 140.5, 128.7, 128.4, 127.2, 126.6,


28

Page 29 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


121.3, 120.6, 120.5, 118.6, 108.8, 100.5, 29.0; HRMS (EI-TOF) m/z: [M]+ Calcd for [C18H14N2] 258.1157, found 258.1156. 5-Methyl-3-(p-tolyl)-5H-pyrido[4,3-b]indole (10c). This compound was obtained as a yellow needle (111.1 mg, 82%); mp 121–126 °C; 1H NMR (400 MHz, CDCl3) δ: 9.29 (s, 1H), 8.11 (d, J = 7.92 Hz, 1H), 7.97 (d, J = 7.92 Hz, 2H), 7.58 (s, 1H), 7.49 (t, J = 7.4 Hz, 1H), 7.37 (d, J = 7.96 Hz, 1H), 7.31– 7.27 (m, 3H), 3.79 (s, 3H), 2.41 (s, 3H);

13

C NMR (100 MHz, CDCl3) δ: 153.5, 146.1, 142.1, 141.4,

138.2, 137.7, 129.4, 127.0, 126.5, 121.3, 120.5, 120.4, 118.4, 108.8, 100.1, 29.0, 21.2; HRMS (EI-TOF) m/z: [M]+ Calcd for [C19H16N2] 272.1313, found 272.1313. 3-(4-(Trifluoromethyl)phenyl)-5H-pyrido[4,3-b]indole (10d). The product was obtained as a red brown needle (117 mg, 75%); mp 124–129 °C; 1H NMR (400 MHz, DMSO-d6) δ: 11.89 (s, 1H), 9.44 (s, 1H), 8.40 (d, J = 8.4 Hz, 2H),8.25 (d, J = 7.6 Hz, 1H), 8.08 (s, 1H), 7.84 (d, J = 8.4 Hz, 2H),7.59 (d, J = 8.4 Hz, 1H),7.49 (t, J = 7.6 Hz, 1H), 7.28 (t, J = 6.9 Hz, 1H);

13

C NMR (100 MHz, DMSO-d6) δ: 149.8,

144.7, 143.6, 142.6, 140.4, 127.3, 127.0, 125.6, 125.5 (q, J = 3.4 Hz, 1C), 120.9, 120.5, 120.3, 119.2, 111.7, 103.4; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C18H12F3N2] 313.0953, found 313.0952. 5-Methyl-3-(4-(trifluoromethyl)phenyl)-5H-pyrido[4,3-b]indole (10e).The product was obtained as a brown needle (128.4 mg, 79%): mp 124−129 °C; 1H NMR (400 MHz, CDCl3) δ: 9.33 (s, 1H), 8.20−8.14 (m, 3H), 7.72 (d, J = 8.0 Hz, 2H), 7.67 (s, 1H), 7.56−7.52 (m, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.33 (t, J = 6.7 Hz, 1H), 3.87 (s, 3H); 13CNMR (100 MHz, CDCl3) δ: 151.8, 145.9, 143.8, 142.4, 141.6, 127.4, 127.0, 125.6 (q, J = 3.8 Hz, 1C), 121.1, 120.8, 119.2, 109.0, 101.1, 29.2; HRMS (EI-TOF) m/z: [M]+ Calcd for [C19H13F3N2] 326.1031, found 326.1030. 8-Chloro-3-phenyl-5H-pyrido[4,3-b]indole (10f). The product was obtained as a yellow needle (112.6 mg, 81%): mp 122–127°C:1H NMR (400 MHz, DMSO-d6) δ:11.90 (s, 1H), 9.44 (s, 1H), 8.35 (s, 1H), 8.16 (d, J = 7.6 Hz, 2H),7.96 (s, 1H),7.57 (d, J = 9.1 Hz, 1H), 7.51–7.45 (m, 3H),7.42–7.38 (m, 1H); 13C NMR (100 MHz, DMSO-d6) δ: 152.3, 145.4, 143.2, 139.7, 138.7, 128.7, 128.5, 126.8, 126.4, 124.5,


29


Page 30 of 38

122.1, 120.3, 118.0, 113.0, 102.5; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C17H12ClN2] 279.0689, found 279.0696. 5-Methyl-3-(thiophen-3-yl)-5H-pyrido[4,3-b]indole (10g).The product was obtained as a brown needle (92.0 mg, 70%): mp 130−135 °C; 1H NMR (400 MHz, CDCl3) δ: 9.24 (s, 1H), 8.11 (d, J = 7.9 Hz, 1H), 7.96 (d, J = 2.4 Hz, 1H), 7.74−7.72 (m, 1H), 7.53−7.48 (m, 2H), 7.41−7.38 (m, 2H), 7.30 (t, J = 7.3 Hz, 1H), 3.82 (s, 3H);

13

CNMR (100 MHz, CDCl3): δ: 149.3, 146.0, 142.0, 141.5, 126.7, 126.3, 126.2,

123.0, 121.3, 120.7, 120.6, 118.4, 108.9, 100.2, 29.1; HRMS (EI-TOF) m/z: [M]+ Calcd for [C16H12N2S] 264.0721, found 264.0721. 5-Phenyl-3-(thiophen-3-yl)-5H-pyrido[4,3-b]indole (10h). The product was obtained as a brown needle (127.5 mg, 78%); mp 128–133 °C: 1H NMR (400 MHz, CDCl3) δ: 9.37 (s, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.82–7.81 (m, 1H), 7.58–7.54 (m, 3H), 7.48–7.45 (m, 3H), 7.38–7.24 (m, 4H), 5.19 (s, 1H);

13

C

NMR (100 MHz, CDCl3) δ: 150.0, 146.0, 142.9, 142.6, 141.5, 136.4, 130.2, 128.3, 127.0, 126.8, 126.4, 126.0, 123.0, 121.8, 121.4, 120.6, 118.9, 110.2, 101.1; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H15N2S] 327.0956, found 327.0942. 5-Methyl-3-phenethyl-5H-pyrido[4,3-b]indole (10i): This compound was obtained as a yellow needle (42 mg, 50 %), mp 124–128 °C; 1H NMR (400 MHz, CDCl3): δ 9.15 (s, 1H), 8.03 (d, J = 7.32 Hz, 1H), 7.45–7.41 (m, 1H), 7.32 (d, J = 7.96 Hz, 1H), 7.25–7.19 (m, 2H), 7.18–7.08 (m, 4H), 6.95 (s, 1H), 3.68 (s, 3H), 3.21–3.17 (m, 2H), 3.10–3.06 (m, 2H);

13

C NMR (100 MHz, CDCl3): δ 145.9, 141.7, 141.4,

141.2, 128.5, 128.3, 126.5, 125.8, 121.3, 120.5, 120.5, 117.9, 108.8, 102.6, 40.6, 36.6, 29.0; HRMS (EITOF) m/z: [M]+ Calcd for [C20H18N2] : 286.1470, found : 286.1470. General Procedure for the Synthesis of Pyrido/quinolino[3,2-c]carbazoles 11a-c. In an oven-dried round bottom flask, a solution of 5-phenyl-2,3,4,7-tetrahydro-pyrido[3,2-c]carbazoles 7, 8, 9 (0.5 mmol) and DDQ in 2.0 mL benzene were added. The resulting reaction mixture was stirred at room temperature for 12h. The reaction mixture was diluted with ethyl acetate (10 mL) and water (15 mL). The layers were separated, and the organic layer was washed with aqueous saturated brine solution and dried over Na2SO4. Organic layer was ACS Paragon Plus Environment

30

Page 31 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


concentrated under reduced pressure. The crude material so obtained was purified by column chromatography on silica gel (100−200) (hexane:ethylacetate; 95/5). The structure and purity of known starting materials were confirmed by comparison of their physical and spectral data (1 H NMR, 13C NMR, and HRMS). 5-Phenyl-7H-pyrido[3,2-c]carbazole (11a). The product was obtained as yellow needle (129.5 mg, 88%); mp 192–197°C; 1H NMR (400 MHz, CDCl3) δ: 9.12 (d, J = 7.8 Hz, 1H), 9.08–9.06 (m, 1H), 8.54 (s, 1H), 8.27 (d, J = 8.7 Hz, 1H), 7.57 (s, 1H), 7.54–7.40 (m, 8H), 7.33–7.30 (m, 1H);13C NMR (100 MHz, CDCl3) δ: 150.0, 146.2, 140.2, 139.1, 138.7, 138.6, 135.0, 130.4, 128.5, 127.7, 125.2, 124.2, 124.0, 122.5, 121.0, 118.5, 116.5, 114.0, 110.8; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C21H15N2] 295.1235, found 295.1223. 7-Methyl-5-phenyl-7H-pyrido[3,2-c]carbazol-3-ol (11b). The product was obtained as yellow needle (133.0 mg, 82%); mp 153–158°C; 1H NMR (400 MHz, CDCl3) δ: 9.89 (s, 1H), 8.90 (d, J = 7.8 Hz, 1H), 8.75–8.74 (m, 1H), 7.86 (s, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.58–7.57 (m, 4H), 7.52–7.46 (m, 2H), 7.31 (t, J = 7.8 Hz, 1H), 4.01 (s, 3H);13C NMR (100 MHz, CDCl3) δ: 149.2, 142.2, ,140.1, 139.8, 139.6, 138.0, 136.7, 130.1, 128.5, 127.5, 124.5, 123.2, 122.3, 122.2,, 119.6, 115.8, 114.9, 113.1, 109.5, 29.3; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C22H17N2O] 325.1341, found 325.1313. 8-Ethyl-11-methyl-5-phenyl-8H-quinolino[7,8-b]carbazole (11c). The product was obtained as yellow needle (131.9 mg, 85%); mp 303–308°C;1H NMR (400 MHz, CDCl3) δ:10.10 (s, 1H), 8.95-8.93 (m, 1H), 8.18 (s, 1H), 7.75-7.73(m, 1H), 7.31 (s, 1H), 7.26-7.23 (m, 2H), 7.17-7.12 (m, 3H),6.98 (t, J = 7.8 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 6.64–6.62 (m, 1H), 6.53 (d, J = 8.2 Hz, 1H), 3.86 (q, J = 7.3 and 14.6 Hz, 2H), 2.51 (s, 3H), 0.81 (t, J = 7.1 Hz, 3H);

13

C NMR (100 MHz, CDCl3) δ:148.1, 147.8, 141.2,

140.3, 137.5, 135.8, 135.1, 133.8, 132.1, 128.8, 128.6, 128.1, 127.6, 127.1, 126.6, 125.3, 124.3, 124.0, 123.3, 121.5, 120.3, 116.3, 108.0, 104.8, 37.3, 21.4, 13.0; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for [C28H23N2] 387.1861, found 387.1870. ASSOCIATED CONTENT ACS Paragon Plus Environment

31


Page 32 of 38

Supporting Information Electronic Supplementary Information (ESI) available: Data and spectral Copies of 1H, 13C NMR, and HRMS for target compounds. CCDC reference number for compound 7b is 1572153. AUTHOR INFORMATION Corresponding Author *E-mail: [email protected] Author Contributions #

SV and PKM authors contributed equally.

ACKNOWLEDGMENT The Research work was supported by SERB and University of Delhi. S.V., M.K., and P.K.M are thankful to CSIR and UGC for fellowship, respectively. REFERENCES 1. (a) Knölker, H.-J.; Reddy K. R. Isolation and synthesis of biologically active carbazole alkaloids. Chem. Rev. 2002, 102, 4303 and references cited therein. (b) Schmidt, A. W.; Reddy, K. R.; Knölker, H.-J. Occurrence, biogenesis, and synthesis of biologically active carbazole alkaloids. Chem. Rev. 2012, 112, 3193 and references cited therein. (c) Reddy P. N.; Padmaja P. Applications of aminocarbazoles in heterocyclic synthesis. ARKIVOC 2015, 244. (d) Kumar, V. P.; Gruner, K. K.; Kataeva, O.; Knölker, H.-J. Total Synthesis of the Biscarbazole Alkaloids Murrafoline A–D by a Domino Sonogashira Coupling/Claisen Rearrangement/Electrocyclization Reaction. Angew. Chem., Int. Ed. 2013, 52, 11073. (e) Bashir, M.; Bano, A.; Ijaz, A. S.; Chaudhary, B. A. Recent developments and biological activities of N-substituted carbazole derivatives: A review. Molecules 2015, 20, 13496.


32

Page 33 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


2. (a) H.-J Knölker and K. R. Reddy, Chapter 4 - Biological and Pharmacological Activities of Carbazole Alkaloids in The Alkaloids, ed. G. A. Cordell, Elsevier Science, New York, 2008, 65, 1–430. (b) Indumathi, T.; Muthusankar, A.; Shanmughavel, P.; Prasad, K. J. R. Synthesis of hetero annulated carbazoles: exploration of in vitro cytotoxicity and molecular docking studies. Med. Chem. Commun. 2013, 4, 450. (c) Murali, K.; Sparkes, H. A.; Prasad, K. J. R. Synthesis of hetero annulated isoxazolo-, pyrido- and pyrimido carbazoles: Screened for in vitro antitumor activity and structure activity relationships, a novel 2-Amino-4-(3'-bromo-4'-methoxyphenyl)-8chloro-11H-pyrimido[4,5-a]carbazole as an antitumor agent. Eur. J. Med. Chem. 2017, 128, 319. (d) Vairavelu, L.; Zeller, M.; Prasad, K. J. R. Solvent-free synthesis of heteroannulated carbazoles: A novel class of anti-tumor agents. Bioorg. Chem. 2014, 54, 12. (e) Le Mée, S.; Pierré, A.; Markovits, J.; Atassi, G.; Jacquemin-Sablon, A.; Saucier, J.-M. S16020–2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Mol. Pharmacol. 1998, 53, 213. 3. (a) Léon, P.; Garbay-Jaureguiberry, C.; Barsi, M. C.; Pecq, J. B. L.; Roques.B. P. Modulation of the Antitumor Activity by Methyl Substitutions in the Series of 7H-Pyridocarbazole Monomers and Dimers. J. Med. Chem. 1987, 30, 2074. (b) Lescot, E.; Muzard, G.; Markovits, J.; Belleney, J.; Roques, B. P.; Pecqt. J.-B. L. Synthesis of 11H-Pyridocarbazoles and Derivatives. Comparison of Their DNA Binding and Antitumor Activity with those of 6H-and 7H-Pyridocarbazoles. J. Med. Chem. 1986, 29, 1731. (c) Pelaprat, D.; Delbarre, A.; Guen, I. L.; Roques, B. P. DNA Intercalating Compounds as Potential Antitumor Agents. 1. Preparation and Properties of 7HPyridocarbazoles. J. Med. Chem. 1980, 23, 1330. (d) Mosher, C.W.; Crews, O.P.; Acton, E.M.; Goodman, L. Preparation and Antitumor Activity of Olivacine and Some New Analogs. J. Med. Chem. 1966, 9, 237. (e) Guillonneau, C.; Pierré, A.; Charton, Y.; Guilbaud, N.; Kraus- Berthier, L.; Léonce, S.; Michel, A.; Bisagni, E.; Atassi, G. Synthesis of 9-O-Substituted Derivatives of 9Hydroxy-5,6-dimethyl-6H- pyrido[4,3-b]carbazole-1-carboxylic Acid (2-(Dimethylamino)ethyl) ACS Paragon Plus Environment

33


Page 34 of 38

amide and their 10- and 11-Methyl Analogues with Improved Antitumor Activity. J. Med. Chem. 1999, 42, 2191. (f) Prudent, R.; Moucadel, V.; Nguyen, C-H.; Barette, C.; Schmidt, F.; Florent, J.-C.; Lafanechère, L.; Sautel, C. F.; Duchemin-Pelletier, E.; Spreux, E.; Filhol, O.; Reiser, J.-B.; Cochet, C. Antitumor Activity of Pyridocarbazole and Benzopyridoindole Derivatives that Inhibit Protein Kinase CK2. Cancer Res. 2010, 70, 9865. 4. (a) Pagano, N.; Wong, E. Y.; Breiding, T.; Liu, H.; Wilbuer, A.; Bregman, H.; Shen, Q.; Diamond, S. L.; Meggers, E. From imide to lactam metallo-pyridocarbazoles: distinct scaffolds for the design of selective protein kinase inhibitors. J. Org. Chem. 2009, 74, 8997. (b) Williams, D. S.; Carroll, P. J.; Meggers, E. Platinum complex as a nanomolar protein kinase inhibitor. Inorg. Chem. 2007, 46, 2944. (c) Pagano, N.; Maksimoska, J.; Bregman, H.; Williams, D. S.; Webster, R. D.; Xuec, F.; Meggers, E. Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand. Org. Biomol. Chem. 2007, 5, 1218. 5. (a) Narasimhan, N. S.; Gokhale, S. M. A New Efficient Synthesis of Pyridocarbazoles. J. Chem. Soc., Chem. Commun. 1985, 0, 86. (b) Manskea, R. F.; Klulka, M. Synthesis of some pyridocarbazoles. J. Am. Chem. Soc. 1950, 72, 4997. (c) Gribble, G. W.; Fletcher, G. L.; Ketcha, D. M.; Rojopadhya, M. Metalated heterocycles in the synthesis of ellipticine analogs. A new route to the 10H-pyrido [2, 3-b] carbazole ring system. J. Org. Chem. 1989, 54, 3264. 6. (a) Gaddam, V.; Nagarajan, R. A one-pot synthetic approach to the functionalized isomeric ellipticine derivatives through an imino Diels–Alder reaction. Tetrahedron Lett. 2009, 50, 1243. (b) Viji, M.; Nagarajan, R. RuCl3/SnCl2 mediated synthesis of pyrrolo[2,3-c]carbazoles and consequent preparation of indolo[2,3-c]carbazoles. Tetrahedron 2012, 68, 2453. (c) Sreenivas, D. K.; Nagarajan, R. Palladium-mediated intramolecular O-arylation: a simple route for the synthesis of quino[2,3-c] and quino[3,2-b]carbazoles. Tetrahedron 2010, 66, 9650. (d) Prakash, K. S.; Nagarajan, R. A General Method for the Synthesis of 5H‐Benzo [b]‐Carbazolo [2, 3‐b]‐and ACS Paragon Plus Environment

34

Page 35 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Indolo [2,3‐b] carbazole Derivatives via Copper (II) Triflate‐Catalyzed Heteroannulation. Adv. Synth. Catal. 2012, 354, 1566. (e) Viji, M.; Nagarajan, R. CAN-Catalyzed Regioselective Synthesis of Pyrido [2, 3-c] carbazoles by the Povarov Reaction. Synthesis 2012, 44, 253. 7. Pedersen, J. M.; Bowman, W. R.; Elsegood, M. R.; Fletcher, A. J.; Lovell, P. J. Synthesis of Ellipticine: A Radical Cascade Protocol to Aryl- and Heteroaryl-Annulated[b]carbazoles. J. Org. Chem. 2005, 70, 10615. 8. Zhang, C.; Das, D.; Seidel, D. Azomethine ylide annulations: facile access to polycyclic ring systems. Chem. Sci. 2011, 2, 233. 9. (a) Reddy, K. R.; Reddy, A. S.; Dhaked, D. K.; Rasheed, S. K.; Pathania, A. S.; Shankar. R.; Malik F.; Das, P. Palladium-catalyzed arylation of 2H-chromene: a new entry to pyrano [2, 3-c] carbazoles. Org. Biomol. Chem. 2015, 13, 9285. (b) S. Samala, G.; Singh, R.; Kumar, R.; S. Ampapathi.; Kundu, B. Metal-Free Decarboxylative Cyclization/Ring Expansion: Construction of Five-, Six-, and Seven-Membered Heterocycles from 2-Alkynyl Benzaldehydes and Cyclic Amino Acids. Angew.Chem. Int. Ed. 2015, 54, 9564. 10. Lin, K.; Jian,Y.; Zhao, P.; Zhao, C.-S.; Pan,W.-D.; Liu, S. A rapid construction of a specific quino[4,3-b] carbazolone system and its application for the synthesis of calothrixin B. Org. Chem. Front. 2018, 5, 590. 11. (a) Ardili, H.; Grigg. R.; Sridharan, V.; Malone, J. A one-pot three carbon decarboxylative ring expansion of cyclic secondary amino acids. X-Ray crystal structure of a substituted 1-azacyclo-octa2,4-diene. J. Chem. Soc., Chem. Commun. 1987, 0, 1296. (b) Rodríguez, N.; Goossen, J. L. Decarboxylative coupling reactions: a modern strategy for C–C-bond formation. Chem. Soc. Rev. 2011, 40, 5030. (c) Bode, J. W.; Fox, R. M.; Baucom, K. D. Chemoselective amide ligations by decarboxylative condensations of N‐alkylhydroxylamines and α‐ketoacids. Angew. Chem. Int. Ed. 2006, 45, 1248. (d) Wang, C.; Tunge, J. A. Decarboxylative ring contractions and olefin ACS Paragon Plus Environment

35


Page 36 of 38

insertions of vinyl oxazinanones. Org. Lett. 2006, 8, 3211. (e) Yan, Y.; Wang, Z. Metal-free intramolecular oxidative decarboxylative amination of primary α-amino acids with product selectivity. Chem. Commun. 2011, 47, 9513. (f) Wang, C.; Piel, I.; Glorius F. Palladiumcatalyzed intramolecular direct arylation of benzoic acids by tandem decarboxylation/C− H activation. J. Am. Chem. Soc. 2009, 131, 4194. 12. (a) Z. Zuo.; MacMillan, D. W. C. Decarboxylative arylation of α-amino acids via photoredox catalysis: a one-step conversion of biomass to drug pharmacophore. J. Am. Chem. Soc. 2014, 136, 5257. (b) Kang, Y.; Seidel, D. Decarboxylative Annulation of α-Amino Acids with γNitroaldehydes. Org. Lett. 2016, 18, 4277. (c) Seidel, D. The azomethine ylide route to amine C– H functionalization: Redox-versions of classic reactions and a pathway to new transformations. Acc. Chem. Res. 2015, 48,317 and references cited therein'. (d) Wang, H.; Xu, W.; Xin, L.; Liu, W.; Wang, Z.; Xu, K. Synthesis of 1,3-Disubstituted Imidazo[1,5-a]pyridines from Amino Acids via Catalytic Decarboxylative Intramolecular Cyclization. J. Org. Chem. 2016, 81, 3681. (e) Wang, Q.; Zhang, S.; Guo, F.; Zhang, B.; Hu, P.; Wang. Z. Natural α-Amino Acids Applied in the Synthesis of Imidazo[1,5-a]N-heterocycles under Mild Conditions. J. Org. Chem. 2012, 77, 11161. (f) Gaddam, V.; Nagarajan, R. An Efficient, One-Pot Synthesis of Isomeric Ellipticine Derivatives through Intramolecular Imino-Diels− Alder Reaction. Org. Lett. 2008, 10, 1975. 13. (a) Mishra, P. K.; Verma, A. K. Metal-free regioselective tandem synthesis of diversely substituted benzimidazo-fused polyheterocycles in aqueous medium. Green Chem. 2016, 18, 6367. (b) Pal, S.; Choudhary, D.; Jainth, M.; Kumar,S.; Tiwari, R. K.; Verma, A. K. Regio- and Stereoselective Domino Synthesis of Oxazolo Fused Pyridoindoles and Benzofurooxazolo Pyridines from ortho-Alkynylarylaldehydes. J. Org. Chem. 2016, 81, 9356. (c) Verma, A. K.; Danodia, A. K.; Saunthwal, R. K.; Patel, M.; Choudhary, D. Palladium-Catalyzed Triple Successive C–H Functionalization: Direct Synthesis of Functionalized Carbazoles from Indoles. Org. Lett. 2015, 17, 3658. (d) Saunthwal, R. K.; Patel, M.; Kumar, S.; Danodia, A. K.; Verma, A. K. Pd (II)‐Catalyzed ACS Paragon Plus Environment

36

Page 37 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


C-H Activation of Styrylindoles: Short, Efficient, and Regioselective Synthesis of Functionalized Carbazoles. Chem. - Eur. J. 2015, 21, 18601. 14. (a) Jha, R. R.; Danodia, A. K.; Kumar, S.; Verma, A. K. Au(III)-catalyzed regio- and stereoselective tandem synthesis of oxazolo fused naphthyridines and isoquinolines from oalkynylaldehydes. Tetrahedron Lett. 2014, 55, 610. (b) Jha, R. R.; Saunthwal, R. K.; Verma, A. K. Stereoselective tandem synthesis of thiazolo fused naphthyridines and thienopyridines from oalkynylaldehydes via Au(III)-catalyzed regioselective 6-endo-dig ring closure. Org. Biomol. Chem. 2014, 12, 552. (c) Kumar, S.; Saunthwal, R. K.; Aggarwal, T.; Kotla, S. K. R.; Verma, A. K. Palladium meets copper: one-pot tandem synthesis of pyrido fused heterocycles via Sonogashira conjoined electrophilic cyclization. Org. Biomol. Chem. 2016, 14, 9063. 15. (a) Tiano, M.; Belmont, P. Rapid access to amino-substituted quinoline,(di) benzofuran, and carbazole heterocycles through an aminobenzannulation reaction. J. Org. Chem. 2008, 73, 4101. (b) Pal, S.; Choudhary, D.; Jainth, M.; Kumar,S.; Tiwari, R. K.; Verma, A. K. Regio- and Stereoselective Domino Synthesis of Oxazolo Fused Pyridoindoles and Benzofurooxazolo Pyridines from ortho-Alkynylarylaldehydes. J. Org. Chem. 2016, 81, 9356. (c) Chaitanya, T. K.; Nagarajan, R. Synthesis of functionalized ellipticinium and ellipticine derivatives via electrophilic cyclization. Org. Biomol. Chem. 2011, 9, 4662. 16. (a) Rahman, M.; Bagdi, A. K.; Mishra, S.; Hajra, A. Functionalization of an sp3 C–H bond via a redox-neutral domino reaction: diastereoselective synthesis of hexahydropyrrolo [2, 1-b] oxazoles. Chem. Commun. 2014, 50, 2951. (b) Yang, D.; Zhao, D.; Mao, L.; Wang, L.; Wang, R. Copper/DIPEA-Catalyzed, Aldehyde-Induced Tandem Decarboxylation–Coupling of Natural αAmino Acids and Phosphites or Secondary Phosphine Oxides. J. Org. Chem. 2011, 76, 6426. (c) Orsini, F.; Pelizzoni, F.; Forte, M.; Destro, R.; Gariboldi, P. 1, 3 Dipolar cycloadditions of azomethine ylides with aromatic aldehydes. Syntheses of 1-oxapyrrolizidines and 1, 3-oxazolidines. Tetrahedron 1988, 44, 519. ACS Paragon Plus Environment

37


Page 38 of 38

17. (a) Otto, R.; Penzis, R.; Gaube, F.; Winckler, T.; Appenroth D.; Fleck, C.; Trankle, C.; Lehmann, J.; Enzensperger, C. Beta and gamma carboline derivatives as potential anti-Alzheimer agents: a comparison. Eur. J. Med. Chem. 2014, 87 63. (b) Zhang, H.; Larock, R. C. Synthesis of Annulated γCarbolines by Palladium-Catalyzed Intramolecular Iminoannulation. Org. Lett. 2002, 4, 3035. 18. (a) Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren,T. A.; Klicic,J. J.; Mainz,D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J. Med. Chem., 2004, 47, 1739. (b) Halgren, T. A.; Murphy,R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. J. Med Chem. 2004, 47, 1750.


38

Transition-Metal-Free Access to Pyridocarbazoles from 2

Recommend Documents